PE20160040A1 - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents

Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a

Info

Publication number
PE20160040A1
PE20160040A1 PE2015001893A PE2015001893A PE20160040A1 PE 20160040 A1 PE20160040 A1 PE 20160040A1 PE 2015001893 A PE2015001893 A PE 2015001893A PE 2015001893 A PE2015001893 A PE 2015001893A PE 20160040 A1 PE20160040 A1 PE 20160040A1
Authority
PE
Peru
Prior art keywords
new type
inhibiting compounds
phosphodiesterase inhibiting
cyc3
cyc1
Prior art date
Application number
PE2015001893A
Other languages
English (en)
Inventor
Jurgen Dinges
Karla Drescher
Jayne Froggett
Michael Ochse
Clarissa Jakob
Katja Jantos
Herve Geneste
Original Assignee
AbbVie Deutschland GmbH and Co KG
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50241454&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Deutschland GmbH and Co KG, Abbvie Inc filed Critical AbbVie Deutschland GmbH and Co KG
Publication of PE20160040A1 publication Critical patent/PE20160040A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compuestos de la formula I, los N-oxidos, tautomeros, y las sales farmaceuticamente aceptables de los mismos; que son inhibidores de la fosfodiesterasa tipo 10. Donde Q es O o S; X1 es N o CH; X2 es O o S; R1 es Y1-Cyc1; R2 es hidrogeno, halogeno, etc.; R3 es Y3-Cyc3, R4 es C1-C4 alquilo, etc.; Y1 , Y3 es enlace, CH2, etc.; Cyc1; Cyc3 son fenilo, etc. Compuestos preferidos son: 5-metil-3-(oxetan-3-ilamino)-7-(piridin-4-il)tieno[2,3-d]piridazin-4(5H)-ona; 5-metil-3-(morfolin-4-il)-7-(piridin-4-il)tieno[2,3-d]piridazin-4(5H)-ona
PE2015001893A 2013-03-13 2014-03-12 Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a PE20160040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779141P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
PE20160040A1 true PE20160040A1 (es) 2016-02-11

Family

ID=50241454

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001893A PE20160040A1 (es) 2013-03-13 2014-03-12 Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a

Country Status (22)

Country Link
US (1) US9200005B2 (es)
EP (1) EP2970328B1 (es)
JP (1) JP2016510786A (es)
KR (1) KR20150127724A (es)
CN (1) CN105358561A (es)
AR (1) AR095267A1 (es)
AU (1) AU2014230825A1 (es)
BR (1) BR112015022094A2 (es)
CA (1) CA2902654A1 (es)
CL (1) CL2015002545A1 (es)
CR (1) CR20150496A (es)
DO (1) DOP2015000214A (es)
HK (1) HK1219273A1 (es)
IL (1) IL240593A0 (es)
MX (1) MX2015012389A (es)
PE (1) PE20160040A1 (es)
PH (1) PH12015501962A1 (es)
RU (1) RU2015143536A (es)
SG (1) SG11201507380PA (es)
TW (1) TW201441230A (es)
UY (1) UY35393A (es)
WO (1) WO2014140086A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN107074824B (zh) * 2014-09-05 2021-01-08 基因泰克公司 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物
EP3242874B1 (en) 2015-01-09 2018-10-31 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
BR112019027717A2 (pt) * 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
CN115838364A (zh) * 2022-12-20 2023-03-24 河南沁朋科技有限公司 一种3,3-双噻吩的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8402000A3 (en) * 1997-12-05 2001-03-12 Astrazeneca Uk Ltd Novel compounds
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
MXPA06014236A (es) 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
WO2006028957A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
US20100222353A1 (en) 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
WO2007098214A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
CA2643963A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
US20090023756A1 (en) 2006-02-23 2009-01-22 Pfizer Inc Substituted quinazolines as pde10 inhibitors
US20070287707A1 (en) 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
CA2644850A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
PT2057153E (pt) 2006-07-10 2012-11-14 Lundbeck & Co As H Derivados (3-aril-piperazin-1-il) de 6,7- dialcoxiquinazolina, 6,7-dialcoxiftalazina e 6,7-dialcoxiisoquinolina
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009025839A2 (en) 2007-08-22 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009029214A1 (en) 2007-08-23 2009-03-05 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
WO2009070583A1 (en) 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
WO2009068246A2 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of treating obesity and metabolic disorders
CA2706866A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
US8389567B2 (en) * 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8927718B2 (en) * 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US20130203756A1 (en) 2010-10-29 2013-08-08 Jamie L. Bunda Isoindoline pde10 inhibitors
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a

Also Published As

Publication number Publication date
HK1219273A1 (zh) 2017-03-31
TW201441230A (zh) 2014-11-01
PH12015501962A1 (en) 2016-01-11
MX2015012389A (es) 2016-03-03
BR112015022094A2 (pt) 2018-06-12
CA2902654A1 (en) 2014-09-18
EP2970328A1 (en) 2016-01-20
KR20150127724A (ko) 2015-11-17
CL2015002545A1 (es) 2016-07-22
US20140275069A1 (en) 2014-09-18
AR095267A1 (es) 2015-09-30
AU2014230825A1 (en) 2015-09-03
WO2014140086A1 (en) 2014-09-18
EP2970328B1 (en) 2017-04-26
US9200005B2 (en) 2015-12-01
CN105358561A (zh) 2016-02-24
CR20150496A (es) 2016-02-19
JP2016510786A (ja) 2016-04-11
DOP2015000214A (es) 2015-12-31
RU2015143536A (ru) 2017-04-18
IL240593A0 (en) 2015-09-24
UY35393A (es) 2014-10-31
SG11201507380PA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
PE20160040A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12017502171B1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
PE20171514A1 (es) Heterociclos biciclicos como inhibidores de fgfr
RS54840B1 (sr) 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
AR098048A1 (es) Inhibidores de fgfr4
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
PE20161246A1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
TN2013000394A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
PE20141938A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
AR091285A1 (es) Inhibidores de bromodominio y sus usos
NZ746607A (en) Substituted reverse pyrimidine bmi-1 inhibitors
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
ECSP109964A (es) Pirimidinas bicíclicas fusionadas
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
PE20170008A1 (es) Compuestos heteroaromaticos y su uso como ligandos de dopamina d1
BR112015032132A2 (pt) cristais de base livre
PE20170640A1 (es) Derivados de quinolizinona como inhibidores de pi3k
PE20091167A1 (es) Derivados heterociclicos con actividad sobre los receptores de ampa
EA201691690A1 (ru) Производные этинила
PE20170009A1 (es) Compuestos heteroaromaticos y su uso como ligandos de dopamina d1

Legal Events

Date Code Title Description
FD Application declared void or lapsed